Tenapanor for constipation-predominant irritable bowel syndrome

Area of Science:

• Gastroenterology
• Pharmacology
• Clinical Medicine

Background:

• Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder impacting quality of life and healthcare costs.
• Key IBS phenotypes include IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and IBS with mixed bowel pattern (IBS-M).
• Current IBS management involves dietary changes, lifestyle modifications, and pharmacotherapy.

Purpose of the Study:

• To review the clinical development program for tenapanor in treating IBS-C.
• To elucidate the mechanism of action and therapeutic benefits of tenapanor.

Main Methods:

• Tenapanor is a selective inhibitor of the intestinal sodium/hydrogen exchanger 3 (NHE3).
• It acts locally within the intestine with minimal systemic absorption.
• Mechanism involves increasing luminal sodium, promoting fluid efflux, and exerting antinociceptive effects.

Main Results:

• Tenapanor was approved by the FDA in September 2019 for IBS-C.
• Clinical trials demonstrate tenapanor's effectiveness in improving bowel movement frequency and stool consistency.
• Significant reduction in abdominal pain associated with IBS-C has been observed.

Conclusions:

• Tenapanor represents a targeted therapeutic option for patients with IBS-C.
• Its unique mechanism addresses both bowel dysfunction and pain in IBS-C.
• Further elaboration on its clinical development program highlights its therapeutic potential.